| abstract |
Provided are a series of small molecule immunoagonists that are homologues, and a bifunctional immunotarget compound having a targeting action and an immunostimulatory function obtained by conjugating a target drug and an agonist. The obtained immunotarget compound is advantageous for enhancing the immunostimulatory effect and antitumor effect of the target drug, as well as the effectiveness against other diseases. Such enhancing effects are provided by the synergistic action of two functions, including inhibition of anti-tumor immune factors (IFN-γ) and pathogenic target sites. |